在肯尼亚优化艾滋病毒耐药性测试实验室网络:从系统工程建模的见解
Yinsheng Wang1, Leonard Kingwara2, Anjuli Dawn Wagner3
1Department of Industrial & Systems Engineering, University of Washington, Seattle, Washington, USA yinshw@uw.edu.
BMJ open
|April 3, 2024
概括
与集中实验室相比,医疗点 (POC) 药物耐药性测试 (DRT) 显著减少了艾滋病毒治疗周转时间 (TAT),并增加了需求能力. 这种建模方法有助于在肯尼亚改善DRT系统的决策.
科学领域:
- 卫生系统研究 卫生系统研究
- 运营研究 运营研究
- 传染病管理 传染病管理
背景情况:
- 艾滋病毒耐药性 (DR) 对艾滋病毒治疗的长期成功构成重大威胁.
- 目前的药物耐药性测试 (DRT) 依赖于昂贵的专业集中实验室,往往导致延误.
- 迫切需要改进DRT系统,特别是对点诊所 (POC) 的测试,以满足需求并缩短周转时间 (TAT).
研究的目的:
- 开发和评估一个优化肯尼亚DRT系统的模型,重点是POCDRT的整合.
- 为了比较一个只有实验室的集中网络与一个优化的POC DRT网络的性能.
- 为改善DRT可访问性和效率提供决策框架.
主要方法:
- 使用整数编程和队列理论开发了一个用户友好的模型.
- 根据目前和理想化的场景,肯尼亚基苏穆县的DRT需求估计.
- 评估了一个只有实验室的集中网络和一个优化的POC DRT网络,包括敏感性分析.
主要成果:
- 只有实验室的集中网络的平均TAT为8.52-8.55个工作日,只能处理1.6%的需求比例.
- POC DRT网络实现了平均TAT为1.13-2.11个工作日,并且可以处理高达4.8%的需求比例.
- 扩大DRT中心显著减少了TAT,而增加国家实验室容量的影响最小;更快的批量分批和运输也是关键因素.
结论:
- 与集中式系统相比,POC DRT网络大大减少了平均TAT,并增加了需求能力.
- 开发的模型为决策者提供了一个明智的框架,以便在肯尼亚实施有效的POC DRT系统.
- 优化的POC DRT网络对于及时的艾滋病毒病例管理至关重要,特别是对于儿童和孕妇等弱势群体.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:14Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).